|
|
|
|
| LEADER |
01441nam a2200253 u 4500 |
| 001 |
EB002010919 |
| 003 |
EBX01000000000000001173818 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
220201 r ||| eng |
| 245 |
0 |
0 |
|a CADTH Canadian Drug Expert Committee recommendation: Dapagliflozin (Forxiga -- AstraZeneca Canada Inc.)
|h Elektronische Ressource
|b indication: in adults, as an adjunct to standard of care therapy, for the treatment of heart failure with reduced ejection fraction (HFrEF) to reduce the risk of cardiovascular death, hospitalization for heart failure (HF) and urgent HF visit
|
| 246 |
3 |
1 |
|a Dapagliflozin (Forxiga -- AstraZeneca Canada Inc.)
|
| 246 |
3 |
1 |
|a Drug reimbursement recommendation Dapagliflozin (Forxiga)
|
| 250 |
|
|
|a Version 1.0
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2021, January 6, 2021
|
| 300 |
|
|
|a 1 PDF file (7 pages)
|
| 710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK572048
|3 Volltext
|
| 082 |
0 |
|
|a 700
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The CADTH Canadian Drug Expert Committee (CDEC) recommends that dapagliflozin (Forxiga) should be reimbursed as an adjunct to standard of care therapy, for the treatment of HFrEF only if certain conditions are met
|